Gregory H. Reaman

The Childhood Cancer Data Initiative: Using the Power of Data to Learn From and Improve Outcomes for Every Child and Young Adult With Pediatric Cancer

Combination Early-Phase Trials of Anticancer Agents in Children and Adolescents

Rare FGFR Oncogenic Alterations in Sequenced Pediatric Solid and Brain Tumors Suggest FGFR Is a Relevant Molecular Target in Childhood Cancer

Paediatric Strategy Forum for medicinal product development in mitogen-activated protein kinase pathway inhibitors

ACCELERATE and European Medicines Agency Paediatric Strategy Forum for medicinal product development of checkpoint inhibitors for use in combination therapy in paediatric patients

ACCELERATE and European Medicine Agency Paediatric Strategy Forum for medicinal product development for mature B-cell malignancies in children

Long-term survivors of childhood cancer: cure and care—the Erice Statement (2006) revised after 10 years (2016)

Prevention of cisplatin‐induced hearing loss in children: Informing the design of future clinical trials

Pharmacokinetic and Pharmacodynamic Properties of Calaspargase Pegol <i>Escherichia coli</i> L-Asparaginase in the Treatment of Patients With Acute Lymphoblastic Leukemia: Results From Children's Oncology Group Study AALL07P4

Intensified chemotherapy without SCT in infant ALL: Results from COG P9407 (Cohort 3)

Erwinia asparaginase achieves therapeutic activity after pegaspargase allergy: a report from the Children’s Oncology Group

Potent obatoclax cytotoxicity and activation of triple death mode killing across infant acute lymphoblastic leukemia

Genetic Alterations Activating Kinase and Cytokine Receptor Signaling in High-Risk Acute Lymphoblastic Leukemia

Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children's Oncology Group Study

Genome-wide association study identifies germline polymorphisms associated with relapse of childhood acute lymphoblastic leukemia